Figure 3.
Incidence of graft-verus-host disease in study (n=34) and contemporaneous control (n=26) patients. (A) Cumulative incidence of grade 2–4 acute GVHD. Study versus control, p=0.08. (B) Cumulative incidence of grade 3–4 acute GVHD. Study versus control, p=0.05. (C) Cumulative incidence of moderate-to-severe chronic GVHD. Study versus control, p=0.4. Dashed line, contemporaneous control patients; Solid line, study patients treated with etanercept.